Literature DB >> 36038666

A senescence stress secretome is a hallmark of therapy-related myeloid neoplasm stromal tissue occurring soon after cytotoxic exposure.

Monika M Kutyna1,2, Chung Hoow Kok1,2, Yoon Lim3, Elizabeth Ngoc Hoa Tran2, David Campbell1,4, Sharon Paton1,2, Chloe Thompson-Peach1,2, Kelly Lim1,2, Dimitrios Cakouros1,2, Agnes Arthur1,2, Timothy Hughes1,2,5, Sharad Kumar1,3, Daniel Thomas1,2, Stan Gronthos1,2, Devendra K Hiwase6,7,8.   

Abstract

Therapy-related myeloid neoplasm (tMN) is considered a direct consequence of DNA damage in hematopoietic stem cells. Despite increasing recognition that altered stroma can also drive leukemogenesis, the functional biology of the tMN microenvironment remains unknown. We performed multiomic (transcriptome, DNA damage response, cytokine secretome and functional profiling) characterization of bone marrow stromal cells from tMN patients. Critically, we also compared (i) patients with myeloid neoplasm and another cancer but without cytotoxic exposure, (ii) typical primary myeloid neoplasm, and (iii) age-matched controls to decipher the microenvironmental changes induced by cytotoxics vs. neoplasia. Strikingly, tMN exhibited a profoundly senescent phenotype with induction of CDKN1A and β-Galactosidase, defective phenotype, and proliferation. Moreover, tMN stroma showed delayed DNA repair and defective adipogenesis. Despite their dormant state, tMN stromal cells were metabolically highly active with a switch toward glycolysis and secreted multiple pro-inflammatory cytokines indicative of a senescent-secretory phenotype that inhibited adipogenesis. Critically, senolytics not only eliminated dormant cells, but also restored adipogenesis. Finally, sequential patient sampling showed senescence phenotypes are induced within months of cytotoxic exposure, well prior to the onset of secondary cancer. Our data underscores a role of senescence in the pathogenesis of tMN and provide a valuable resource for future therapeutics.
© 2022. Crown.

Entities:  

Year:  2022        PMID: 36038666     DOI: 10.1038/s41375-022-01686-y

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   12.883


  48 in total

1.  Sipa1 deficiency-induced bone marrow niche alterations lead to the initiation of myeloproliferative neoplasm.

Authors:  Pingnan Xiao; Monika Dolinska; Lakshmi Sandhow; Makoto Kondo; Anne-Sofie Johansson; Thibault Bouderlique; Ying Zhao; Xidan Li; Marios Dimitriou; George Z Rassidakis; Eva Hellström-Lindberg; Nagahiro Minato; Julian Walfridsson; David T Scadden; Mikael Sigvardsson; Hong Qian
Journal:  Blood Adv       Date:  2018-03-13

Review 2.  Therapy-related myeloid neoplasms: when genetics and environment collide.

Authors:  Megan E McNerney; Lucy A Godley; Michelle M Le Beau
Journal:  Nat Rev Cancer       Date:  2017-08-24       Impact factor: 60.716

3.  Stroma-mediated dysregulation of myelopoiesis in mice lacking I kappa B alpha.

Authors:  Rudolf A Rupec; Franziska Jundt; Bernd Rebholz; Birgit Eckelt; Günther Weindl; Thomas Herzinger; Michael J Flaig; Sabine Moosmann; Gerd Plewig; Bernd Dörken; Irmgard Förster; Ralf Huss; Klaus Pfeffer
Journal:  Immunity       Date:  2005-04       Impact factor: 31.745

4.  Dynamics of clonal evolution in myelodysplastic syndromes.

Authors:  Hideki Makishima; Tetsuichi Yoshizato; Kenichi Yoshida; Mikkael A Sekeres; Tomas Radivoyevitch; Hiromichi Suzuki; Bartlomiej Przychodzen; Yasunobu Nagata; Manja Meggendorfer; Masashi Sanada; Yusuke Okuno; Cassandra Hirsch; Teodora Kuzmanovic; Yusuke Sato; Aiko Sato-Otsubo; Thomas LaFramboise; Naoko Hosono; Yuichi Shiraishi; Kenichi Chiba; Claudia Haferlach; Wolfgang Kern; Hiroko Tanaka; Yusuke Shiozawa; Inés Gómez-Seguí; Holleh D Husseinzadeh; Swapna Thota; Kathryn M Guinta; Brittney Dienes; Tsuyoshi Nakamaki; Shuichi Miyawaki; Yogen Saunthararajah; Shigeru Chiba; Satoru Miyano; Lee-Yung Shih; Torsten Haferlach; Seishi Ogawa; Jaroslaw P Maciejewski
Journal:  Nat Genet       Date:  2016-12-19       Impact factor: 38.330

5.  A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency.

Authors:  Carl R Walkley; Gemma Haines Olsen; Sebastian Dworkin; Stewart A Fabb; Jeremy Swann; Grant A McArthur; Susan V Westmoreland; Pierre Chambon; David T Scadden; Louise E Purton
Journal:  Cell       Date:  2007-06-15       Impact factor: 41.582

6.  Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia.

Authors:  Jane E Churpek; Rafael Marquez; Barbara Neistadt; Kimberly Claussen; Ming K Lee; Matthew M Churpek; Dezheng Huo; Howard Weiner; Mekhala Bannerjee; Lucy A Godley; Michelle M Le Beau; Colin C Pritchard; Tom Walsh; Mary-Claire King; Olufunmilayo I Olopade; Richard A Larson
Journal:  Cancer       Date:  2015-12-07       Impact factor: 6.860

7.  The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution.

Authors:  Hamish S Scott; Christopher N Hahn; Devendra K Hiwase; Deepak Singhal; Li Yan A Wee; Monika M Kutyna; Rakchha Chhetri; Joel Geoghegan; Andreas W Schreiber; Jinghua Feng; Paul P-S Wang; Milena Babic; Wendy T Parker; Smita Hiwase; Suzanne Edwards; Sarah Moore; Susan Branford; Teodora Kuzmanovic; Nimit Singhal; Raghu Gowda; Anna L Brown; Peer Arts; Luen B To; Peter G Bardy; Ian D Lewis; Richard J D'Andrea; Jaroslaw P Maciejewski
Journal:  Leukemia       Date:  2019-05-14       Impact factor: 11.528

8.  Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia.

Authors:  Marc H G P Raaijmakers; Siddhartha Mukherjee; Shangqin Guo; Siyi Zhang; Tatsuya Kobayashi; Jesse A Schoonmaker; Benjamin L Ebert; Fatima Al-Shahrour; Robert P Hasserjian; Edward O Scadden; Zinmar Aung; Marc Matza; Matthias Merkenschlager; Charles Lin; Johanna M Rommens; David T Scadden
Journal:  Nature       Date:  2010-03-21       Impact factor: 49.962

9.  Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer.

Authors:  Deepak Singhal; Christopher N Hahn; Lucy A Godley; Devendra K Hiwase; Simone Feurstein; Li Yan A Wee; Luke Moma; Monika M Kutyna; Rakchha Chhetri; Leila Eshraghi; Andreas W Schreiber; Jinghua Feng; Paul P-S Wang; Milena Babic; Wendy T Parker; Song Gao; Sarah Moore; Soma Das; David Thomas; Swetansu Pattnaik; Anna L Brown; Richard J D'Andrea; Nicola K Poplawski; Daniel Thomas; Hamish S Scott
Journal:  Leukemia       Date:  2021-04-13       Impact factor: 12.883

10.  Cytotoxic Therapy-Induced Effects on Both Hematopoietic and Marrow Stromal Cells Promotes Therapy-Related Myeloid Neoplasms.

Authors:  Angela Stoddart; Jianghong Wang; Anthony A Fernald; Elizabeth M Davis; Camille R Johnson; Chunmei Hu; Jason X Cheng; Megan E McNerney; Michelle M Le Beau
Journal:  Blood Cancer Discov       Date:  2020-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.